Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.48 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | KCNA1 | Q09470 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25532686 | 1.00 | DPP4 (0.48) | DPP4LOXL2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL22694641 | 0.83 | DPP4 (0.52) | DPP4LOXL2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3466160 | 0.78 | SLC6A4 (0.52) | DPP4LOXL2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL13357550 | 0.78 | ANPEP (0.48) | DPP4LOXL2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL11971835 | 0.78 | DPP4 (0.47) | DPP4LOXL2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL10002431 | 0.78 | DPP4 (0.47) | DPP4LOXL2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL744414 | 0.78 | SLC6A4 (0.52) | DPP4LOXL2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL19897932 | 0.78 | DPP4 (0.47) | DPP4LOXL2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6854249 | 0.78 | SLC6A4 (0.52) | DPP4LOXL2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL28852060 | 0.78 | DPP4 (0.47) | DPP4LOXL2SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117731675-A | Medical application of pentacyclic triterpene derivative, pentacyclic triterpene derivative and pharmaceutical composition containing pentacyclic triterpene derivative | 上海科技大学 | 2024-03-22 | — | — | CN | disclosed |
| US-9650358-B2 | Pyridine CDK9 kinase inhibitors | ABBVIE INC. (US) | 2017-05-16 | — | — | US | disclosed |
| EP-2970200-A1 | PYRIDINE CDK9 KINASE INHIBITORS | Abbvie Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| CN-105189481-A | Pyridine cdk9 kinase inhibitors | ABBVIE INC | 2015-12-23 | — | — | CN | disclosed |
| WO-2014160017-A1 | PYRIDINE CDK9 KINASE INHIBITORS | ABBVIE INC. (US) | 2014-10-02 | — | — | WO | disclosed |
| US-20140275011-A1 | PYRIDINE CDK9 KINASE INHIBITORS | ABBVIE INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-7709473-B2 | Substituted 2H-[1,2,4]triazolo[4,3-a]pyrazines as GSK-3 inhibitors | PFIZER INC. (US) | 2010-05-04 | — | — | US | disclosed |
| US-20070249612-A1 | Substituted 2H-[1,2,4]Triazolo[4,3-A]Pyrazines as Gsk-3 Inhibitors | BENBOW JOHN W | 2007-10-25 | — | — | US | disclosed |
| EP-1678180-B1 | SUBSTITUTED 2H-[1,2,4]TRIAZOLO 4,3-A PYRAZINES AS GSK-3 INHIBITORS | PFIZER PROD INC (US) | 2007-08-08 | — | — | EP | disclosed |
| US-7202245-B2 | Substituted 4-amino[1,2,4]triazolo[4,3-a] quinoxalines | PFIZER INC. (US) | 2007-04-10 | — | — | US | disclosed |
| CN-1094718-A | Bicyclic fibrinogen antagonists | SMITHKLINE BEECHAM CORP (US) | 1994-11-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249612-A1 | Substituted 2H-[1,2,4]Triazolo[4,3-A]Pyrazines as Gsk-3 Inhibitors | GSK3B, GSK3A, GSKIP | DPP4 1086/4885LOXL2 3599/4885SLC6A2 4036/4885 |
| US-20140275011-A1 | PYRIDINE CDK9 KINASE INHIBITORS | CDK9, CDK19, CDK6 | DPP4 3403/4885LOXL2 3340/4885SLC6A2 4689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.